These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26074442)

  • 1. Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease.
    Ishii H; Aoyama T; Takahashi H; Kumada Y; Kamoi D; Sakakibara T; Umemoto N; Suzuki S; Tanaka A; Ito Y; Murohara T
    J Cardiol; 2016 Feb; 67(2):199-204. PubMed ID: 26074442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.
    Ishii H; Kumada Y; Toriyama T; Aoyama T; Takahashi H; Yamada S; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1034-40. PubMed ID: 18322041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilostazol for primary prevention of stroke in peripheral artery disease: a population-based longitudinal study in Taiwan.
    Lee WH; Chu CY; Hsu PC; Su HM; Lin TH; Voon WC; Lai WT; Sheu SH
    Thromb Res; 2013 Aug; 132(2):190-5. PubMed ID: 23433530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Cilostazol Therapy in Hemodialysis Patients with Asymptomatic Peripheral Arterial Disease: A Retrospective Cohort Study.
    Lim PS; Jeng Y; Wu MY; Pai MA; Wu TK; Chen CH
    Biomed Res Int; 2016; 2016():8236903. PubMed ID: 27747241
    [No Abstract]   [Full Text] [Related]  

  • 5. Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
    Iida O; Yokoi H; Soga Y; Inoue N; Suzuki K; Yokoi Y; Kawasaki D; Zen K; Urasawa K; Shintani Y; Miyamoto A; Hirano K; Miyashita Y; Tsuchiya T; Shinozaki N; Nakamura M; Isshiki T; Hamasaki T; Nanto S;
    Circulation; 2013 Jun; 127(23):2307-15. PubMed ID: 23652861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effectiveness of Cilostazol in Patients with Hemodialysis with Peripheral Artery Disease.
    Wu CK; Lin CH; Yar N; Kao ZK; Yang YB; Chen YY
    J Atheroscler Thromb; 2023 Aug; 30(8):943-955. PubMed ID: 36216573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-eluting stenting for femoropopliteal lesions, followed by cilostazol treatment, reduces stent restenosis in patients with symptomatic peripheral artery disease.
    Zen K; Takahara M; Iida O; Soga Y; Kawasaki D; Nanto S; Yokoi H; Matoba S;
    J Vasc Surg; 2017 Mar; 65(3):720-725. PubMed ID: 28073668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practice-based evidence: profiling the safety of cilostazol by text-mining of clinical notes.
    Leeper NJ; Bauer-Mehren A; Iyer SV; Lependu P; Olson C; Shah NH
    PLoS One; 2013; 8(5):e63499. PubMed ID: 23717437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restenosis after stent implantation for superficial femoral artery disease in patients treated with cilostazol.
    Soga Y; Iida O; Hirano K; Suzuki K; Yokoi H; Nobuyoshi M
    Catheter Cardiovasc Interv; 2012 Mar; 79(4):541-8. PubMed ID: 21805619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of cilostazol on arterial wound healing: a retrospective analysis.
    Resnick KA; Gordon IL
    Ann Vasc Surg; 2014 Aug; 28(6):1513-21. PubMed ID: 24561209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
    Hiatt WR; Money SR; Brass EP
    J Vasc Surg; 2008 Feb; 47(2):330-336. PubMed ID: 18155871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized pilot trial between prostaglandin I2 analog and anti-platelet drugs on peripheral arterial disease in hemodialysis patients.
    Ohtake T; Sato M; Nakazawa R; Kondoh M; Miyaji T; Moriya H; Hidaka S; Kobayashi S
    Ther Apher Dial; 2014 Feb; 18(1):1-8. PubMed ID: 24499078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial.
    Goldenberg NA; Krantz MJ; Hiatt WR
    Vasc Med; 2012 Jun; 17(3):145-54. PubMed ID: 22615190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients.
    Shiohira S; Yoshida T; Sugiura H; Yoshida S; Mitobe M; Shimada K; Ohba T; Tsuchiya K; Kabaya T; Nitta K
    Clin Exp Nephrol; 2011 Dec; 15(6):893-9. PubMed ID: 21773691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.
    Soga Y; Yokoi H; Kawasaki T; Nakashima H; Tsurugida M; Hikichi Y; Nobuyoshi M
    J Am Coll Cardiol; 2009 Jan; 53(1):48-53. PubMed ID: 19118724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of cilostazol in patients with peripheral arterial disease: results of a national physician survey.
    de Donato G; Setacci F; Galzerano G; Mele M; Ruzzi U; Setacci C
    J Cardiovasc Surg (Torino); 2016 Jun; 57(3):457-65. PubMed ID: 27094424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilostazol for peripheral arterial disease could reduce stroke risk?
    Watson A; Mikhailidis DP; Stansby G
    Thromb Res; 2013 Aug; 132(2):149-50. PubMed ID: 23622557
    [No Abstract]   [Full Text] [Related]  

  • 18. Cilostazol Improves Wound Healing in Patients Undergoing Open Bypass for Ischemic Tissue Loss: A Propensity Score Matching Analysis.
    Mii S; Guntani A; Kawakubo E; Tanaka K; Kyuragi R
    Ann Vasc Surg; 2018 May; 49():30-38. PubMed ID: 29455014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; McEneny J; Young IS; Lee B; Soong CV
    Eur J Vasc Endovasc Surg; 2009 Mar; 37(3):326-35. PubMed ID: 19112032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of cilostazol in ischemic stroke patients with peripheral arterial disease (SPAD): protocol of a randomized, double-blind, placebo-controlled multicenter trial.
    Jeng JS; Sun Y; Lee JT; Lin RT; Chen CH; Po HL; Lin HJ; Liu CH; Sun MH; Sun MC; Chern CM; Lien LM; Chiu HC; Hu HH; Chiou HY; Chen ST; Ma H; Hsu CY;
    Int J Stroke; 2015 Jan; 10(1):123-7. PubMed ID: 25394855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.